Skip to content

Korea Equity Lens

  • About
  • IR Room
  • Research
    • Semiconductors
    • Bio & Healthcare
    • Defense
    • EV & Battery
    • Automotive
    • Energy
    • Robotics
    • Shipbuilding
  • Toggle search form
  • [Research] LigaChem Biosciences (141080) – IBK Securities | Enhertu Resistance · Clinical Readouts · Tech Transfer / 2025-11-27 Research
  • [Research] LigaChem Biosciences (141080) – Kyobo Securities | Pipeline Clinical Progress · IND Filings · Tech Transfer / 2026-04-01 Research
  • [Research] LigaChem Biosciences (141080) – Yuanta Securities | Payload Chemistry · Safety Profile · Differentiation / 2025-05-22 Research
  • [IR] Samsung Electro-Mechanics (009150) – Q4 2023 Earnings Presentation / 2024-01-31 IR Room
  • [Research] LIG D&A (079550) – Kiwoom Securities | Defense Export Expansion · GR Turnaround · 2026E Upward / 2026-02-19 Research
  • [Research] Alteogen (196170) – Shinhan Securities | 2 Out-Licensing Deals in Q1 · Biogen Deal Analysis · Major Catalysts Ahead from April / 2026-03-27 Research
  • [IR] SK hynix (000660 / SKHY) – Q2 2025 Earnings Presentation / 2025-07-24 IR Room
  • [Research] Samsung SDI (006400) – Mirae Asset Securities | SDC Stake Monetization · Tesla ESS Business Expansion · Earnings Trough / 2026-02-20 Research

[Research] Samsung Electro-Mechanics (009150) – Mirae Asset Securities | De-China Supply Chain · FC-BGA Geopolitics · MLCC Strategic Asset / 2026-06-05

Posted on June 5, 2026August 24, 2026 By ksb220805@gmail.com

Brokerage : Mirae Asset Securities

Analyst : Junseo Park (park.junseo@miraeasset.com)

Investment Rating : BUY (Maintained)

Target Price : KRW 2,800,000 (Maintained)

Core Momentum : Structural re-rating driven by non-China FC-BGA supply chain leadership, KRW 8 Trillion multi-year CAPEX deployment across 2026–2027, and strategic asset status for high-capacitance MLCCs

📊 1. [Valuation & Key Financial Metrics]

  • Rating & Target Price: BUY (Maintained) / Target Price KRW 2,800,000 (Maintained) (Closing price KRW 1,716,000 as of June 4, 2026; upside potential 63.2%)
  • Key Financial Metrics & Forecast:
    • Revenue (KRW): 2024 KRW 10.294 Trillion → 2025 KRW 11.314 Trillion → 2026(E) KRW 13.520 Trillion → 2027(E) KRW 16.465 Trillion → 2028(E) KRW 22.238 Trillion
    • Operating Profit (KRW): 2024 KRW 735.0 Billion → 2025 KRW 913.0 Billion → 2026(E) KRW 1.562 Trillion → 2027(E) KRW 3.408 Trillion → 2028(E) KRW 5.870 Trillion
    • Operating Profit Margin (OPM): 2024 7.1% → 2025 8.1% → 2026(E) 11.6% → 2027(E) 20.7% → 2028(E) 26.4%
    • Net Profit (Controlling) (KRW): 2024 KRW 679.0 Billion → 2025 KRW 706.0 Billion → 2026(E) KRW 1.313 Trillion → 2027(E) KRW 2.827 Trillion → 2028(E) KRW 4.925 Trillion
    • EPS (KRW): 2024 KRW 8,752 → 2025 KRW 9,099 → 2026(E) KRW 16,914 → 2027(E) KRW 36,428 → 2028(E) KRW 63,466
    • Valuation Multiples (PER / PBR / ROE):
      • 2024: PER 14.1x, PBR 1.1x, ROE 8.2%
      • 2025: PER 28.0x, PBR 2.3x, ROE 7.7%
      • 2026(E): PER 101.5x, PBR 13.7x, ROE 13.0%
      • 2027(E): PER 47.1x, PBR 10.8x, ROE 23.5%
      • 2028(E): PER 27.0x, PBR 10.2x, ROE 35.9%
  • 2026 Annual Consensus Comparison:
    • 2026 Operating Profit estimated at KRW 1.562 Trillion (vs. consensus of KRW 1.589 Trillion)

🚀 2. [Market Opportunities & Business Outlook]

  • De-China Supply Chain Restructuring & Geopolitical Premium:
    • Geopolitical Tailwinds: With global PCB production concentrated in mainland China and AI substrates classified as national security assets, North American Big Tech is prioritizing non-China procurement. As one of the few non-China suppliers with top-tier technical capabilities, SEMCO commands high pricing and allocation visibility.
    • Massive CAPEX Deployment: FC-BGA CAPEX projected at KRW 3 Trillion in 2026 and KRW 5 Trillion in 2027 (KRW 8 Trillion combined), supported by customer prepayments, grants, and long-term exclusive contracts.
    • Big Tech Customer Footprint: Secured first-vendor position for LPU inference FC-BGAs for a North American GPU giant, actively supplying server FC-BGAs to a North American semiconductor maker, and currently in discussions for next-gen AI chip adoption with another North American Big Tech client.
  • Structural Pricing Power in FC-BGA Substrates:
    • Rising accelerator demand from CoWoS expansion, coupled with expanding layer counts, larger substrate areas, and raw material bottlenecks (CCL, T-glass), ensures sustained structural price increases. Selective bidding focused on high-spec products.
  • MLCC Transition to Strategic Asset:
    • Escalating power requirements in AI servers drive surging demand for high-capacitance, high-reliability MLCCs.
    • Lengthening global lead times and depleted inventory cycles drive a structural up-cycle across the entire components business.

📝 Editor’s Comment (Perspective)

The analyst views Samsung Electro-Mechanics not merely as a passive component manufacturer, but as an indispensable non-China strategic partner securing a geopolitical premium as AI packaging substrates become critical national security assets. This perspective looks past short-term quarterly fluctuations to emphasize structural multiple expansion, supported by KRW 8 Trillion in planned FC-BGA CAPEX over 2026–2027, first-vendor status in next-generation inference LPUs, and customer-backed exclusive commitments.

To evaluate whether this investment thesis unfolds as anticipated, key verification checkpoints include the progress of FC-BGA CAPEX execution (KRW 3 Trillion in 2026, KRW 5 Trillion in 2027), mass production milestones for North American GPU inference LPUs, additional design wins across North American hyperscalers, and the persistence of elongated lead times for server-grade MLCCs. Progress on these fronts can be tracked via upcoming quarterly earnings announcements, official investor relations presentations, and periodic regulatory filings.

📢 Disclaimer & Source

Source: This content has been structured and newly written based on officially disclosed financial facts and data from brokerage reports.

Investment Risk Notice: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific securities. All investment decisions and financial responsibilities rest entirely with the investor.

Contact: Compliance and Copyright Inquiries (ksb220805@gmail.com)

Search by
Company Name or Stock Ticker.
Research, Semiconductors

Post navigation

Previous Post: [Research] Alteogen (196170) – Daishin Securities | Key US Patent Risks Significantly Eased · New Licensing Catalysts · Keytruda SC Milestones / 2026-06-02
Next Post: [Research] SK hynix (000660 / SKHY) – Mirae Asset | AI Infrastructure · LTA · HBM Demand / 2026-06-09

Related Posts

  • [Research] SK hynix (000660 / SKHY) – Daishin | Memory ASP · Earnings Upgrades · Valuation Appeal / 2026-03-16 Research
  • [Research] Samsung Electro-Mechanics (009150) – Daishin Securities | Supply Shortage · High-End Mix · Earnings Upward Revisions / 2026-07-07 Research
  • [Research] Samsung Electro-Mechanics (009150) – Hana Securities | MLCC & FCBGA Shortage · LTA Expansion · 2027 Peer Multiple / 2026-05-04 Research
  • [Research] Samsung SDI (006400) – iM Securities | AIDC ESS Demand · US Regulation Benefits · Profit Turnaround / 2026-06-30 Research
  • [Research] SK hynix (000660 / SKHY) – Mirae Asset | ADR Listing · SOX Inclusion · HBM Pricing / 2026-06-25 Research
  • [Research] Alteogen (196170) – Shinhan Securities | Halozyme Patent Invalidated · Key Overhangs Materially Eased · Target Price Raised / 2026-05-14 Research
  • [Research] Samsung Electro-Mechanics (009150) – iM Securities | Silicon Capacitor LTA · Fabless Model · SOTP Re-rating / 2026-05-21 Research
  • [Research] Samsung Biologics (207940) – Hana Securities | Rockville Ramp-up · Business Scale Expansion · Revenue Visibility / 2026-07-24 Research
  • [Research] Alteogen (196170) – Hana Securities | Exclusive Biogen Licensing Deal · ~USD 40M Q1 Cumulative Upfronts · Rich Q2 Catalysts Ahead / 2026-03-26 Research
  • [Research] LigaChem Biosciences (141080) – Mirae Asset Securities | Clinical Milestones · Commercialization Potential · Platform PoC / 2025-05-23 Research
  • [Research] Samsung SDI (006400) – Hana Securities | Stepwise Loss Reduction · Strong ESS BBU Shipments · 4Q26 Turnaround / 2026-02-03 Research
  • [Research] SK hynix (000660 / SKHY) – Hana | Commodity DRAM Pricing · LTA · Multiple Expansion / 2026-06-26 Research
  • [Research] SK hynix (000660 / SKHY) – Shinhan | Supply Constraints · Memory Pricing · LTA / 2026-04-24 Research
  • [Research] Samsung Electro-Mechanics (009150) – Mirae Asset Securities | Long-term Exclusive Contracts · 2029 Target EPS · Structural ASP Hikes / 2026-06-01 Research

Copyright © 2026 Korea Equity Lens.

Powered by PressBook News Dark theme